Odyssey Therapeutics presented at the Stifel 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026. The company, founded in 2021, reported cash of $433 million as of June 30, 2024, giving it a runway that extends into the second half of 2028.
For its lead asset OD-001, a RIPK2 scaffolding inhibitor targeting ulcerative colitis, Odyssey highlighted a 25% clinical remission rate in treatment‑experienced patients from a Phase IIa study. The drug achieved 100% scaffolding inhibition and robust downstream cytokine suppression, with about 70% IC90 coverage at a 10 mg twice‑daily dose and maximal 90% inhibition at 20 mg twice‑daily. A lower‑dose cohort is being expanded from four to fifteen patients, while the higher‑dose cohort includes forty‑one participants. Odyssey plans a Phase IIa combination study pairing OD-001 with vedolizumab versus vedolizumab plus placebo, and will present OD-001 data at the United European Gastroenterology conference on October 20, 2024, with a poster expected at the American College of Gastroenterology meeting on October 13, 2024.
OD-002, an SLC15A4 inhibitor aimed at autoimmune and cutaneous lupus indications, showed single‑digit animal potency and high selectivity in preclinical work, supporting a projected once‑daily human dose below 20 mg. The company intends to initiate a basket study with cutaneous lupus erythematosus as the initial proof‑of‑concept.
OD-003, a TNFR2 agonist developed with TRex Bio, demonstrated Treg trafficking to the brain and therapeutic efficacy in an experimental autoimmune encephalomyelitis model where an IL‑2 comparator failed. The agonist also activated homing markers such as CCR8 and the tissue‑repair factor BATF.
On the market side, Odyssey’s stock closed at $21.58, down 9.25% on the day of the forum. The shares have risen roughly 42% over the prior six months, giving the firm a market capitalization of about $1.12 billion. Analyst price targets range from $29 to $44. The next earnings release is scheduled for December 2, 2026.
